Arcutis Biotherapeutics
ARQT
ARQT
239 hedge funds and large institutions have $1.95B invested in Arcutis Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 65 increasing their positions, 81 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
239
Holders Change
+32
Holders Change %
+15.46%
% of All Funds
3.25%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
64
Increased
65
Reduced
81
Closed
30
Calls
$13.1M
Puts
$4.26M
Net Calls
+$8.83M
Net Calls Change
+$4.57M
Top Buyers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$22.9M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$6.41M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.9M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.07M |
| 5 |
RA
Royce & Associates
New York
|
+$4.19M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$28.7M |
| 2 |
Jennison Associates
New York
|
-$15.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.4M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$10.5M |
| 5 |
JPMorgan Chase & Co
New York
|
-$9.35M |
